News

Vevo Therapeutics Open Sources Tahoe-100M, the World's Largest Single-Cell Dataset, as the Inaugural Contribution to Arc Institute's New Virtual Cell Atlas

300 million single cell atlas now accessible to the scientific community comprised of Vevo's Tahoe-100M, mapping 60,000 drug-patient interactions, and Arc's AI-curated scBaseCamp 200 million cell dataset. Generated using Vevo's Mosaic platform, Tahoe-100M leveraged Parse Biosciences' GigaLab for...

Junevity Raises $10M to Develop Cell Reset Therapeutics for Longevity

Founded by a team of experts in aging biology, machine learning and drug development and based on pioneering research for resetting cell health by Dr. Janine Sengstack of UCSF. Junevity’s RESET platform uses large-scale human data and AI to identify novel transcription factor targets and repress...

Leveragen Announces Strategic Collaboration with Moonlight Bio to Advance T Cell Therapies Using Proprietary Fully Human Single-Domain Antibody Technology

Leveragen Inc., a Boston-based biotech company specializing in next-generation genetic models for antibody discovery, today announced a strategic collaboration with Moonlight Bio, a Seattle-based biotech company pioneering advanced T-cell therapies. This partnership aims to develop cutting-edge T-...

PreludeDx Receives FDA Breakthrough Device Designation for DCISionRT® Test for DCIS Breast Cancer Patients PreludeDx (PRNewsfoto/PreludeDx)

Prelude Corporation, a leader in precision diagnostics for early-stage breast cancer, announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Device designation for its DCISionRT® test. Thea Tlsty is the lead UCSF inventor. MORE

Venova Medical Announces First Subjects Enrolled in VENOS-2 IDE Study of the Velocity Percutaneous AVF System

The VENOS-2 prospective, multicenter study is being performed under an Investigational Device Exemption (IDE) granted by the FDA and will evaluate the feasibility of the company's Velocity pAVF System which is designed to enable a minimally invasive approach for the creation of an AV fistula for...

ArsenalBio and Bristol Myers Squibb Achieve Milestone to Advance Next-Generation T Cell Therapies for Solid Tumors

Arsenal Biosciences, a clinical-stage programmable cell therapy company focused on engineering advanced CAR T cell therapies for solid tumors, today announced that Bristol Myers Squibb has exercised its exclusive license option for ArsenalBio’s AB-4000 series, the lead collaboration program...

Vevo Therapeutics to Open Source Milestone Tahoe-100M Dataset

Vevo Therapeutics, a biotechnology company using its Mosaic technology and next-generation AI to uncover better drugs for more patients, announced today that it would open-source its historic Tahoe-100M dataset in collaboration with NVIDIA's biology foundation model research team. The NVIDIA team...

Alessa Therapeutics Announces First Patient Enrolled in the Enolen Study for Localized Drug Delivery for Prostate Cancer

Alessa Therapeutics, a privately held drug development company developing an innovative and proprietary localized drug delivery technology for the treatment of prostate disease, announced the enrollment of the first patient in the company’s Enolen® clinical study at the National Cancer Institute (...

Sana’s cell therapy may be ‘transformative cure’ for type 1 diabetes: analysts

Sana Biotechnology has shared early data for its investigational allogeneic cell therapy being studied in one patient with type 1 diabetes, sending the company’s share price up by about 200%. The data “pave the way for a potentially transformative cure,” for a disease that affects more than 1.7...

Aer Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of Fexlamose in Chronic Obstructive Pulmonary Disease

Study AER-01-002 uses a novel and precision imaging strategy to enroll 100 mucus plug-high chronic obstructive pulmonary disease (COPD) patients AER-01-002 is well-powered to determine if 28-days of once-daily dosing of fexlamose is safe and improves lung function Fexlamose has been shown in Phase...